<DOC>
	<DOCNO>NCT00002524</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient AIDS-related lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With AIDS-Related Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Develop effective chemotherapy regimen mild immunosuppressive myelosuppressive property treat patient AIDS-related lymphoma ( ARL ) severe T4 lymphopenia . II . Estimate CR rate , lymphoma-free survival , overall survival non-T4 lymphopenic patient patient present nonbulky Ann Arbor stage I ARL treat standard regimen know effectiveness . III . Evaluate effect long-term outlook concurrent antiretroviral therapy , prophylactic antibiosis trimethoprim/sulfamethoxazole aerosolize pentamidine , prn use granulocyte colony-stimulating factor severe myelosuppression . OUTLINE : Patients assign Regimens A , B , C accord histology extent disease degree immunosuppression follow : Regimen A : Patients Ann Arbor stage I intermediate grade immunoblastic lymphoma measurable nonbulky disease ( le 7 cm ) , low LDH ( less 686 ) , prior opportunistic infection irrespective T4 count ; also nonmeasurable stage I extranodal primary ( infiltration le 2/3 organ site , e.g. , stomach , rectum , esophagus , sinus cavity ) irrespective T4 count . Regimen B : All patient ( except primary brain lymphoma patient ) assign Regimen A T4 count least 200 history opportunistic infection ; include stage small noncleaved cell lymphoma bulky stage I stag II-IV intermediate grade immunoblastic lymphoma . Regimen C : Patients assign Regimen A B , i.e. , T4 count less 200 and/or history opportunistic infection primary brain lymphoma . The following acronym use : ARA-C Cytarabine , NSC-63878 BLEO Bleomycin , NSC-125066 CDDP Cisplatin , NSC-119875 CF Leucovorin calcium , NSC-3590 CTX Cyclophosphamide , NSC-26271 DOX Doxorubicin , NSC-123127 5-FU Fluorouracil , NSC-19893 G-CSF Granulocyte Colony-Stimulating Factor ( Amgen ) , NSC-614629 IFF Ifosfamide , NSC-109723 MePRDL Methylprednisolone succinate Mesna Mercaptoethane sulfonate , NSC-113891 MTX Methotrexate , NSC-740 PRED Prednisone , NSC-10023 VCR Vincristine , NSC-67574 VP-16 Etoposide , NSC-141540 ZDV Zidovudine , NSC-602670 Regimen A : 5-Drug Combination Chemotherapy follow Radiotherapy . CHOP-BLEO : CTX ; DOX ; VCR ; PRED ; BLEO ; follow involved-field irradiation megavoltage equipment . Regimen B : 4-Drug Combination Chemotherapy alternate 3-Drug Combination Chemotherapy follow , indicate , Radiotherapy . ASHAP : DOX ; MePRDL ; ARA-C ; CDDP ; alternate IMVP-16 : IFF/Mesna ; MTX/CF ; VP-16 ; follow , select patient initially bulky localized disease , involved-field irradiation megavoltage equipment . Regimen C : 2-Drug Combination Chemotherapy Drug Modulation follow , indicate , Radiotherapy . FLEP : 5-FU/CF/CDDP ; follow , select patient initially bulky localized disease , involved-field irradiation megavoltage equipment . Prior start chemotherapy , patient primary brain lymphoma receive course cranial irradiation use accelerator beam photon energy 6-15 MV . PROJECTED ACCRUAL : Up 92 patient ( 10 Regimen A , 28 Regimen B , 54 Regimen C ) enter 3 year . If CRs among first 6 patient Regimens A B first 19 patient Regimen C , accrual regimen cease . If 4 infectious death occur among first 10 patient rate disease progression exceed 20 % regimen , accrual regimen cease .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , AIDS-Related</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously untreated , HIVrelated intermediate highgrade lymphoma previous diagnosis Kaposi 's sarcoma Pathology review M.D . Anderson Cancer Center PATIENT CHARACTERISTICS : Age : Over 15 Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : For patient T4 le 200 primary brain lymphoma : Creatinine great 2.0 mg/dL ( unless entry approve principal investigator ) Other : Serious intercurrent illness must discuss principal investigator Infectious disease consultation require complex infection Medications condition allow provided adverse interaction protocol therapy occur No previously diagnose Kaposi 's sarcoma malignancy PRIOR CONCURRENT THERAPY : No prior therapy lymphoma No concurrent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
</DOC>